Spine Journal - 2026-10-18 - Journal Article; Review
Management Strategies and Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus Native Vertebral Osteomyelitis: A Systematic Review and Meta-Analysis.
Pourghazi F, Alavi SMA, Baaklini G, Nassr A, Freedman BA, Matsuo T, Tande AJ, Berbari EF
Topics
Key Takeaway
Pooled treatment success for MRSA native vertebral osteomyelitis was 84.9% (95% CI 76.7–90.7%) across 30 studies and 677 patients, with a reinfection rate of 15.3% and mortality of 3.1%.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This systematic review and meta-analysis evaluated antimicrobial and surgical management strategies for MRSA native vertebral osteomyelitis across 30 studies (n=677). Vancomycin-based regimens were the dominant antimicrobial strategy, with IV therapy typically lasting 4–8 weeks; surgical approaches ranged from debridement to decompression with fusion. Pooled treatment success was 84.9%, reinfection 15.3%, and all-cause mortality 3.1%, though subgroup analyses by treatment type were not feasible due to inconsistent reporting.
Key Limitation
Subgroup analyses by treatment modality (surgical vs. medical, vancomycin vs. alternative agents, duration of therapy) were not feasible due to heterogeneous and inconsistently reported data across included studies, making it impossible to attribute outcomes to specific management strategies.
Original Abstract
BACKGROUND CONTEXT
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of native vertebral osteomyelitis (NVO) and is associated with persistent infection, complications, prolonged hospitalization, and increased mortality.
PURPOSE
We conducted this systematic review and meta-analysis to evaluate the antimicrobial and surgical approaches used for MRSA NVO and their associated clinical outcomes.
STUDY SETTING
Systematic review and meta-analysis.
METHODS
A systematic literature search of MEDLINE, Scopus, and Web of Science was conducted on November 27, 2025. Studies were eligible if they included adults with MRSA NVO, evaluated medical or surgical treatment strategies, reported clinical outcomes, and included at least five patients. Two reviewers independently screened studies and extracted data. Risk of bias was assessed using the Newcastle-Ottawa Scale and the Murad et al. tool. Random-effects models were used to pool proportions of treatment success, reinfection, and mortality.
RESULTS
Thirty studies including 677 patients were included. Treatment strategies were heterogeneous and included prolonged anti-MRSA antimicrobial therapy and surgical approaches ranging from debridement and drainage to decompression and spinal stabilization or fusion. Vancomycin-based regimens were the most frequently reported antimicrobial strategy. Among studies reporting treatment duration, intravenous therapy commonly ranged from 4 to 8 weeks, with some patients receiving oral step-down or suppressive therapy. The pooled treatment success rate was 84.9% (95% CI, 76.7%-90.7%), pooled reinfection rate was 15.3% (95% CI, 9.5%-23.6%), and pooled mortality rate was 3.1% (95% CI, 0.8%-10.8%). Subgroup analyses were not feasible because treatment-specific data were limited and inconsistently reported.
CONCLUSIONS
Management of MRSA NVO varied substantially across studies, with vancomycin-based antimicrobial therapy and diverse surgical strategies commonly reported. Pooled outcomes showed high treatment success with lower rates of reinfection and mortality. The substantial clinical and methodological heterogeneity of the available evidence highlights the need for prospective studies with standardized treatment and outcome reporting.